Sica Domenic A, Mannino Rosemarie
Division of Nephrology, Virginia Commonwealth University Health System, Richmond, VA 23298-0160, USA.
J Clin Hypertens (Greenwich). 2007 Sep;9(9):723-7. doi: 10.1111/j.1524-6175.2007.06296.x.
Antihypertensive medication use can be associated with a reduction in hemoglobin concentration. The magnitude of such a change is generally small, but in certain instances it can be extreme enough to produce a clinically significant degree of anemia. The mechanistic basis for antihypertensive medication-related changes in hemoglobin concentration include hemodilution, hemolytic anemia, and suppression of red blood cell production, as this occurs most commonly with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. A reduction in hemoglobin concentration in a patient who is receiving treatment for hypertension and does not have an obvious source of blood loss should account for potential antihypertensive therapy involvement.
使用抗高血压药物可能与血红蛋白浓度降低有关。这种变化的幅度通常较小,但在某些情况下可能会极端到产生具有临床意义的贫血程度。抗高血压药物相关的血红蛋白浓度变化的机制基础包括血液稀释、溶血性贫血和红细胞生成受抑制,因为这种情况最常发生在使用血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂时。对于正在接受高血压治疗且没有明显失血来源的患者,血红蛋白浓度降低应考虑潜在的抗高血压治疗因素。